Loading...
XKRX
003520
Market cap156mUSD
Aug 24, Last price  
1,201.00KRW
1D
1.18%
1Q
-16.36%
Jan 2017
-86.38%
Name

Yungjin Pharm Co Ltd

Chart & performance

D1W1MN
XKRX:003520 chart
P/E
—
P/S
0.86
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.24%
Rev. gr., 5y
4.05%
Revenues
254.26b
+0.88%
109,659,792,000110,865,010,000103,376,306,000116,317,389,550112,105,475,000137,688,400,340156,622,683,050167,569,401,350170,203,311,310193,133,853,130195,008,846,800186,408,689,480220,516,292,420208,463,639,670196,067,242,000218,380,987,000234,902,460,000252,040,229,000254,255,894,000
Net income
-228m
L
-14,580,311,000-6,733,543,000-4,347,977,000-2,308,665,7302,580,830,0001,794,227,97011,742,329,880909,091,9503,386,324,3304,202,183,1201,867,719,950-6,100,940,1105,029,923,810-133,121,310-11,582,456,000-21,961,039,000-3,875,543,0001,232,792,000-227,661,000
CFO
10.24b
-52.88%
-1,338,311,0007,293,678,000-20,150,00010,008,673,3308,496,954,0002,379,190,2905,953,588,4206,216,130,7108,801,551,2303,111,936,5003,151,782,2301,274,179,0809,282,594,81014,497,598,0008,367,764,000-11,609,700,000-12,499,480,00021,740,849,00010,244,414,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Yungjin Pharm. Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. Its products include cephalosporin, antibiotics, drugs for the central nervous system, cardiovascular, endocrine system, urinary system, respiratory, anti-inflammatory and analgesics, anti-histamine, anti-fungal, total nutrition, vitamin and supplement, cosmetics, and tonic drinks. The company was founded on July 16, 1962 and is headquartered in Seoul, South Korea.
URL
http://www.yungjin.co.kr/
IPO date
Jun 25, 1973
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT